Purdue Pharma ruling could lead to more Ch15 cases, ABI panellists say

Purdue Pharma ruling could lead to more Ch15 cases, ABI panellists say

The US could be put at a competitive disadvantage if the country’s highest court finds that third-party releases granted to Purdue Pharma’s non-debtor owners are not authorised by the Bankruptcy Code, according to a pair of prominent academics.

Unlock unlimited access to all Global Restructuring Review content